MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jhep.2025.09.033

Медицинская библиотека · Journal of hepatology · 2025

HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses.

Yuan Hongfeng, Zhao Lina, Yang Guang, Zhang Shuai, Lv Pan, Zhang Shuqin, Wang Yufei, Cai Qiaomei, Shan Changliang, Liu Yunxia, Geng Yu, Zhang Huihui, Gao Xiuzhu, Wang Xiaomei, Miao Zhenchuan, Yin Ming, Zhao Man, Niu Junqi, Hao Xishan, Zhang Xiaodong

СтатьяПеревод в очереди

Аннотация

BACKGROUND & AIMS: Chronic infection with HBV remains a significant public health concern, and current therapies are inadequate. Here, we report that HBx-elevated heat shock protein B1 (HSPB1) contributes to the regulation of HBV covalently closed circular DNA (cccDNA) and hepatic immune responses.

METHODS

Molecular and cellular in vitro assays were employed to investigate the effects and underlying mechanisms of HSPB1 on HBV cccDNA and HBV replication in HBV-infected cells. The antiviral efficacy of candidate agents targeting cccDNA and the immune response was assessed in HBV-infected cells, human liver chimeric mice, and hydrodynamic injection-based HBV-persistent immunocompetent C57BL/6 mice.

RESULTS

HSPB1 enhanced cccDNA stability by reducing the recruitment and binding of APOBEC3A/APOBEC3B to cccDNA. Interaction with HBx increased cellular HSPB1 levels by decreasing its ubiquitination, while enhanced phosphorylation promoted nuclear accumulation of HSPB1. Therapeutically, we developed a peptide, D-TK, derived from the HBXIP peptide sequence that targets HBx and limits cccDNA by blocking the interaction between HSPB1 and HBx, ultimately resulting in reduced HBV replication. Nobly, D-TK reduced the frequency of regulatory T cells and enhanced the frequency and activity of CD8+ T cells through HSPB1, thereby contributing to suppression of HBV replication.

CONCLUSIONS

HSPB1 represents a novel therapeutic target by modulating HBV cccDNA and immune responses in the liver. By suppressing cccDNA and enhancing immune responses, D-TK represents a promising therapeutic candidate for HBV treatment.

IMPACT AND IMPLICATIONS: Chronic infection with HBV remains a significant global health concern, and current therapeutic options are inadequate. In this study, we demonstrate that HBV X protein (HBx)-induced elevation of HSPB1 contributes to the regulation of HBV covalently closed circular DNA (cccDNA) and hepatic immune responses. We engineered a peptide, D-TK, that targets HBx, effectively suppresses cccDNA, and activates immune responses through HSPB1. Our findings offer new insights into the mechanism by which HBx-induced HSPB1 modulates HBV cccDNA and immune regulation in the liver.

Для цитирования: Yuan Hongfeng, Zhao Lina, Yang Guang, Zhang Shuai, Lv Pan, Zhang Shuqin, Wang Yufei, Cai Qiaomei, Shan Changliang, Liu Yunxia, Geng Yu, Zhang Huihui, Gao Xiuzhu, Wang Xiaomei, Miao Zhenchuan, Yin Ming, Zhao Man, Niu Junqi, Hao Xishan, Zhang Xiaodong. HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses.. Journal of hepatology. 2025. DOI: 10.1016/j.jhep.2025.09.033.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.